However, the positive impact of metformin was primarily observed in hormone-receptor-positive patients, suggesting potential improvement in prognosis associated with diabetes and insulin treatment in HER2-positive and hormone-receptor-positive breast cancer patients. Here, ERBB2 is linked to breast carcinoma.